17 December 2024

AOTI, INC. (the "Company" or "Group" or "AOTI")

Grant of performance share awards to CFO under Long Term Incentive Plan

AOTI, INC., a medical technology group focused on the durable healing of wounds and prevention of amputations, announces that on 17th December 2024, the Company granted awards over ordinary shares in the form of nominal cost options (Performance Awards) under the AOTI Long Term Incentive Plan (LTIP) to Jayesh Pankhania, CFO, who joined AOTI in June 2024 and is a Person Discharging Managerial Responsibilities (PDMR), as detailed below:

In determining the number of awards, the Company has used a share price of 132p, being the IPO price.

The Performance Awards will vest three years from the grant date conditional on meeting three-year performance conditions as described below.

40% of an award is subject to a revenue growth performance condition measured over a three-year period ending 31 December 2026.

30% of an award is subject to a relative total shareholder return (TSR) performance condition measured over three years from the date of the IPO. AOTI's TSR performance will be measured against a sector peer group of UK, US and other internationally quoted companies with 25% of this portion of the award vesting at median performance rising on a straight line to full vesting at upper quartile performance.

30% of an award is subject to an absolute total shareholder return performance condition measured over three years from the date of the IPO. Vesting will commence from zero at 10% compound annual growth rising on a straight line to full vesting at 20% compound annual growth.

END

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂^®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO₂^® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂^® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net

​